Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 254 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "HFpEF" Clear all
Recruiting Not applicable Interventional

Leg Heat Therapy in Heart Failure With Preserved Ejection Fraction

NCT06388226
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Leg heat therapy, Leg sham therapy
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 17, 2026, 6:09 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

NCT06763549
View directory record Official record
Conditions
Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions
SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 17, 2026, 6:09 PM EDT
Recruiting Not applicable Interventional

PREACTIVE: Preconditioning Exercise Intervention to Improve Symptoms and Quality of Life in Comorbid Atrial Fibrillation and HFpEF

NCT07324772
View directory record Official record
Conditions
Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal), Persistent Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
progressive resistance training, combined aerobic + resistance training
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
60 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Recruiting Not applicable Interventional

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

NCT06593314
View directory record Official record
Conditions
Heart Failure, Diabetes
Interventions
Message with EchoGo, Standard Message
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

NCT04945460
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years to 85 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Not listed Not applicable Interventional

The Effect of a High Fiber Diet and High-Intensity Interval Exercise in Patients With HFpEF

NCT05236413
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
High Intensity Interval Exercise, Dietary Approaches to Stop Hypertension (DASH) Diet, Exercise + DASH Diet
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 17, 2026, 6:09 PM EDT
Recruiting Not applicable Interventional

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

NCT05934487
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Interventions
Cordella™ Pulmonary Artery Sensor System
Device
Lead sponsor
Endotronix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 1 Interventional

Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults

NCT04996719
View directory record Official record
Conditions
Heart Failure
Interventions
Rapamune
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 17, 2026, 6:09 PM EDT
Not listed Phase 1Phase 2 Interventional

Mechanisms of Semaglutide Therapy in Heart Failure Patients

NCT06541509
View directory record Official record
Conditions
Heart Failure, Obesity
Interventions
Semaglutide
Drug
Lead sponsor
University Medical Centre Ljubljana
Other
Eligibility
20 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 17, 2026, 6:09 PM EDT
Recruiting Not applicable Interventional

Inspiratory Muscle Training in HFpEF

NCT06510231
View directory record Official record
Conditions
Heart Failure
Interventions
Inspiratory Muscle Training
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 2 Interventional Results available

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

NCT03547583
View directory record Official record
Conditions
Chronic Heart Failure With Preserved Ejection Fraction
Interventions
Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
29
States / cities
Beverly Hills, California • Carmichael, California • West Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 17, 2026, 6:09 PM EDT
Recruiting Not applicable Interventional

The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF)

NCT06702501
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
PeriCut Catheter System performs minimally invasive pericardiotomy
Device
Lead sponsor
Heart Failure Solutions, Inc.
Industry
Eligibility
30 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

NCT04986202
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
AZD4831, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Not applicable Interventional

Minimally Invasive Pericardiotomy as a New Treatment for Heart Failure

NCT03923673
View directory record Official record
Conditions
Heart Failure
Interventions
Pericardiotomy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Sep 17, 2026, 6:09 PM EDT
Completed No phase listed Observational

Mechanisms in Heart Failure With Normal EF

NCT00587808
View directory record Official record
Conditions
Heart Failure
Interventions
RHC with VO2 consumption
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 17, 2026, 6:09 PM EDT
Recruiting Phase 2 Interventional

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

NCT06762964
View directory record Official record
Conditions
Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin tablet, Placebo Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Recruiting Phase 2 Interventional

Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation

NCT06130059
View directory record Official record
Conditions
Heart Failure, Inflammation
Interventions
Low Dose Colchicine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

NCT05284617
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
HU6, Placebo
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
40 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Beverly Hills, California • Torrance, California • Hialeah, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Not applicable Interventional

Weight Loss as Therapy for Heart Failure With Preserved Ejection Fraction

NCT02911337
View directory record Official record
Conditions
Heart Failure, Diastolic, Weight Loss
Interventions
lifestyle modification
Dietary Supplement
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 17, 2026, 6:09 PM EDT
Recruiting Phase 2 Interventional

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

NCT06793371
View directory record Official record
Conditions
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
26
States / cities
Fairhope, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Not applicable Interventional Results available

Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome

NCT03170375
View directory record Official record
Conditions
Heart Failure
Interventions
Performance of WHEELS-I in promoting DASH/SRD adoption
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 17, 2026, 6:09 PM EDT
Recruiting Phase 3 Interventional

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

NCT07567001
View directory record Official record
Conditions
Obesity, Heart Failure
Interventions
NNC0487-0111, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
5,610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
206
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 173 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Exercise Intolerance in Heart Failure

NCT03775577
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)

NCT01942395
View directory record Official record
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease
Interventions
DASH/sodium-restricted diet (DASH/SRD), Control Diet
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 17, 2026, 6:09 PM EDT